Figure 2.

Primary and secondary wCIRUS‐RBDQ outcome. Patient and partner reported dream enactment events were collected every day in weeklong diary reports and then averaged in 4‐week epochs that represent the four phases of the study (pretreatment, early and late treatment, and follow‐up). The primary endpoint of the study was the late treatment epoch (weeks 5–8). Panel (A) shows that there was no significant difference between melatonin (in blue) and placebo (in red) on the number of RBD events (primary outcome; P for difference = 0.92). The absolute range of RBD events per week underlying the data at baseline were 0 to 28 (28 being an outlier) for the melatonin group and 0 to 18 events per week for the placebo group. Panel (B) shows that there was no significant difference between groups on the number of nights in which a dream enactment event occurred RBD events (secondary outcome 1; P for difference = 0.56). The error bars drawn are the standard errors. [Color figure can be viewed at http://wileyonlinelibrary.com]